Our preclinical data suggest that co-targeting of DYRK1A and menin or BCL2 has particular activity against this high-risk leukemia subtype that may warrant clinical investigation in patients in the future to address issues of chemoresistance and relapse risk. This evidence concerns the gene BCL2 and leukemia.